Fibrosis and angiogenesis

Current Opinion in Nephrology and Hypertension

Volumn 9, Issue 4, 2000, Pages 413-418

  Kalluri, Raghu ^a   Sukhatme, Vikas P ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; ENDOSTATIN; FIBROBLAST GROWTH FACTOR 2; RESTIN; TRANSFORMING GROWTH FACTOR BETA1;

ANGIOGENESIS; BASEMENT MEMBRANE; EXTRACELLULAR MATRIX; FIBROSIS; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANIMALS; FIBRINOLYSIS; FIBROBLAST GROWTH FACTOR 2; FIBROSIS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 0033936187     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200007000-00013     Document Type: Review

References (78)

1. 1 Folkman J, D'Amore PA. Blood vessel formation: what is its molecular basis? [Comment]. Cell 1996; 87:1153-1155.
2. 2 Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1:27-31.
3. 3 Chawla PS, Keelan MH, Kipshidze N. Angiogenesis for the treatment of vascular diseases [Editorial] [in Process Citation]. Int Angiol 1999; 18:185-192. A good review for an overview of anti-angiogenesis therapy for various vascular diseases.
4. 4 Albini A, Noonan D, Santi L. Angiogenesis at the interface between basic and clinical research. Int J Biol Markers 1999; 14:202-206. A good bench-to-bedside summary of angiogenesis research.
5. 5 Hanahan D, Weinberg R. Hallmarks of cancer. Cell 2000; 100:57-70. The most comprehensive cancer review this year yet.
6. 6 Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994; 331:1286-1292.
7. 7 Friedman SL. Cytokines and fibrogenesis. Semin Liver Dis 1999; 19:129-140. A good review of recent research to understand fibrosis and the role of cytokines in its inception and progression.
8. 8 Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275:2247-2250. A short review of hepatic fibrosis.
9. 9 Branton MH, Kopp JB. TGF-beta and fibrosis. Microbes Infect 1999; 1:1349-1365. A well-written review on the role of TGF-β in fibrosis.
10. 10 Tsukamoto H. Cytokine regulation of hepatic stellate cells in liver fibrosis. Alcohol Clin Exp Res 1999; 23:911-916.
11. 11 Kunkel SL, Lukacs NW, Strieter RM, et al. The role of chemokines in the immunopathology of pulmonary disease. Forum (Genova) 1999; 9:339-355.
12. 12 Okada H, Strutz F, Danoff TM, et al. Possible mechanisms of renal fibrosis. Contrib Nephrol 1996; 118:147-154.
13. 13 Distler O, Rinkes B, Hohenleutner U, et al. Expression of RANTES in biopsies of skin and upper gastrointestinal tract from patients with systemic sclerosis. Rheumatol Int 1999; 19:39-46.
14. 14 Keane MP, Belperio, JA, Moore TA, et al. Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis. J Immunol 1999; 162:5511-5518. A recent study with CXC chemokine, MIP-2, in a model for pulmonary fibrosis. This study proves that MIP-2 can attenuate fibrosis.
15. 15 Okada H, Danoff TM, Kalluri R, et al. Early role of Fsp1 in epithelial-mesenchymal transformation. Am J Physiol 1997; 273:F563-574.
16. 16 Keane MP, Strieter RM. The role of CXC chemokines in the regulation of angiogenesis. Chem Immunol 1999; 72:86-101. A good review of chemokines and angiogenesis.
17. 17 Hasegawa T, Kimura A, Miyataka, M, et al. Basic fibroblast growth factor increases regional myocardial blood flow and salvages myocardium in the infarct border zone in a rabbit model of acute myocardial infarction. Angiology 1999; 50:487-495.
18. 18 Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86:353-364.
19. 19 Folkman J. Angiogenesis and angiogenesis inhibition: an overview. Exs 1997; 79:1-8.
20. 20 Bouck N, Stellmach V, Hsu SC. How tumors become angiogenic. Adv Cancer Res 1996; 69:135-174.
21. 21 Bouck N. Tumor angiogenesis: the role of oncogenes and tumor suppressor genes. Cancer Cells 1990; 2:179-185.
22. 22 Bouck N. Angiogenesis: a mechanism by which oncogenes and tumor suppressor genes regulate tumorigenesis. Cancer Treat Res 1992; 63:359-371.
23. 23 Folkman J. Incipient angiogenesis [Editorial; Comment]. J Natl Cancer Inst 2000; 92:94-95.
24. 24 Browder T, Folkman J, Pirie-Shepherd S. The hemostatic system as a regulator of angiogenesis. J Biol Chem 2000; 275:1521-1524.
25. 25 Aumailley M, Timpl R. Attachment of cells to basement membrane collagen type IV. J Cell Biol 1986; 103:1569-1575.
26. 26 Aumailley M, Specks U, Timpl R. Cell adhesion to type-VI collagen. Biochem Soc Trans 1991; 19:843-847.
27. 27 Paulsson M. Basement membrane proteins: structure, assembly, and cellular interactions. Crit Rev Biochem Mol Biol 1992; 27:93-127.
28. 28 Timpl R. Macromolecular organization of basement membranes. Curr Opin Cell Biol 1996; 8:618-624.
29. 29 Prockop DJ, Kivirikko KI. Collagens: molecular biology, diseases, and potentials for therapy. Annu Rev Biochem 1995; 64:403-434.
30. 30 Madri JA, Pratt BM. Endothelial cell-matrix interactions: in vitro models of angiogenesis. J Histochem Cytochem 1986; 34:85-91.
31. 31 Madri JA. Extracellular matrix modulation of vascular cell behaviour. Transplant Immunol 1997; 5:179-183.
32. 32 O'Reilly MS, Boehm T, Shing N, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88:277-285.
33. 33 Kamphaus GD, Colorado PC, Panka DJ, et al. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 2000; 275:1209-1215. A new inhibitor of angiogenesis derived from type IV collagen.
34. 34 Ramchandran R, Dhanabal M, Volk R, et al. Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin. Biochem Biophys Res Commun 1999; 255:735-739. A new inhibitor of angiogenesis derived from type XV collagen.
35. 35 Colorado EA. Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res 2000; 1.
36. 36 Maeshima Y, Colorado PC, Torre A, et al. Distinct anti-tumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem 2000.
37. 37 Folkman J, Shing Y. Angiogenesis. [Review]. J Biol Chem 1992; 267:10931-10934.
38. 38 Haas TL, Madri JA. Extracellular matrix-driven matrix metalloproteinase production in endothelial cells: implications for angiogenesis. Trends Cardiovasc Med 1999; 9:70-77.
39. 39 Nelson AR, Fingleton B, Rothenberg ML, et al. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000; 18:1135-1149. This is well-written review of MMP and their role in various diseases.
40. 40 Liaw L, Crawford HC. Functions of the extracellular matrix and matrix degrading proteases during tumor progression. Braz J Med Biol Res 1999; 32:805-812.
41. 41 Massague J. The transforming growth factor-beta family. Annu Rev Cell Biol 1990; 6:597-641.
42. 42 Roberts AB. Molecular and cell biology of TGF-beta. Miner Electrolyte Metabol 1998; 24:111-119.
43. 43 Roberts AB, Sporn MB. Regulation of endothelial cell growth, architecture, and matrix synthesis by TGF-beta. Am Rev Respir Dis 1989; 140:1126-1128.
44. 44 Massague J. TGF-beta signal transduction. Annu Rev Biochem 1998; 67:753-791.
45. 45 Border WA, Noble NA. Cytokines in kidney disease: the role of transforming growth factor-beta. Am J Kidney Dis 1993; 22:105-113.
46. 46 Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol 1998; 16:137-161.
47. 47 Noble NA, Harper JR, Border WA. In vivo interactions of TGF-beta and extracellular matrix. Prog Growth Factor Res 1992; 4:369-382.
48. 48 Yamamoto T, Noble NA, Miller DE, Border WA. Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis. Kidney Int 1994; 45:916-927.
49. 49 Roberts AB, Sporn MB, Assoian RK, et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986; 83:4167-4171.
50. 50 Border WA, NA Noble, Yamamoto ?, et al. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 1992; 360:361-364.
51. 51 Harper JR, Spiro RC, Gaarde WA, et al. Role of transforming growth factor beta and decorin in controlling fibrosis. Methods Enzymol 1994; 245:241-254.
52. 52 Border WA, Noble NA. Targeting TGF-beta for treatment of disease [Comment]. Nat Med 1995; 1:1000-1001.
53. 53 Yang X, Castilla LH, Xu Z, et al. Angiogenesis defects and mesenchymal apoptosis in mice lacking SMAD5. Development 1999; 126:1571-1580.
54. 54 Gleizes PE, Rifkin DB. Activation of latent TGF-beta. A required mechanism for vascular integrity [in French]. Pathol Biol (Paris) 1999; 47:322-329.
55. 55 D'Amore PA, Smith SR. Growth factor effects on cells of the vascular wall: a survey. Growth Factors 1993; 8:61-75.
56. 56 Ananth S, Knebelmann B, Gruning W, et al. Transforming growth factor beta 1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma. Cancer Res 1999; 59:2210-2216. One of the first studies to show the potential of anti-TGF-β antibody as an inhibitor of angiogenesis.
57. 57 Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism [see Comments]. Nature 1999; 397:530-534. This study uses cyclosporine and anti-TGF-β antibody to control tumor growth.
58. 58 Okada-Ban M, Grassi M, Plouet J, et al. Impact on tumor angiogenesis and tumor progression of expression of the 18kd and 24kd isoforms of FGF-2 [in French]. Pathol Biol (Paris) 1999; 47:375-379.
59. 59 Cronauer MV, Stadlmann S, Klocker H, et al. Basic fibroblast growth factor synthesis by human peritoneal mesothelial cells: induction by interleukin-1. Am J Pathol 1999; 155:1977-1984.
60. 60 Ohshima K, Sugihara M, Suzumiya J, et al. Basic fibroblast growth factor and fibrosis in Hodgkin's disease. Pathol Res Pract 1999; 195:149-155.
61. 61 Shinozaki M, Kawara S, Hayashi N, et al. Induction of subcutaneous tissue fibrosis in newborn mice by transforming growth factor beta-simultaneous application with basic fibroblast growth factor causes persistent fibrosis [corrected and republished in Biochem Biophys Res Commun 1997; 240:292-297]. Biochem Biophys Res Commun 1997; 237:292-296.
62. 62 Floege J, Kriz W, Schulze M, et al. Basic fibroblast growth factor augments podocyte injury and induces glomerulosclerosis in rats with experimental membranous nephropathy. J Clin Invest 1995; 96:2809-2819.
63. 63 Floege J, Burg M, Hugo C, et al. Endogenous fibroblast growth factor-2 mediates cytotoxicity in experimental mesangioproliferative glomerulonephritis. J Am Soc Nephrol 1998; 9:792-801.
64. 64 Hasebe T, Imoto S, Ogura T, et al. Significance of basic fibroblast growth factor and fibroblast growth factor receptor protein expression in the formation of fibrotic focus in invasive ductal carcinoma of the breast. Jpn J Cancer Res 1997; 88:877-885.
65. 65 Martyre MC, Le Bousse-Kerdiles MC, Romquin N, et al. Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis [see Comments]. Br J Haematol 1997; 97:441-448.
66. 66 Jin-no K, Tanimizu M, Hyodo I, et al. Plasma level of basic fibroblast growth factor increases with progression of chronic liver disease. J Gastroenterol 1997; 32:119-121.
67. 67 Stein-Oakley AN, Maguire JA, Dowling J, et al. Altered expression of fibrogenic growth factors in IgA nephropathy and focal and segmental glomerulosclerosis. Kidney Int 1997; 51:195-204.
68. 68 Folkman J, Klagsburn M, Sassa J, et al. A heparin-binding angiogenic protein-basic fibroblast growth factor-is stored within basement membrane. Am J Pathol 1988; 130:393-400.
69. 69 Folkman J. Tumor angiogenesis and tissue factor [Comment]. Nat Med 1996; 2:167-168.
70. 70 Folkman J. Endothelial cells and angiogenic growth factors in cancer growth and metastasis. Introduction. [Review]. Cancer Metast Rev 1990; 9:171-174.
71. 71 Rosengart TK, Budenbender KT, Duenas M, et al. Therapeutic angiogenesis: a comparative study of the angiogenic potential of acidic fibroblast growth factor and heparin. J Vasc Surg 1997; 26:302-312.
72. 72 Rosengart TK, Patel SR, Crystal RG. Therapeutic angiogenesis: protein and gene therapy delivery strategies. J Cardiovasc Risk 1999; 6:29-40.
73. 73 Sisson TH, Hattori N, Xu Y, et al. Treatment of bleomycin-induced pulmonary fibrosis by transfer of urokinase-type plasminogen activator genes. Hum Gene Ther 1999; 10:2315-2323.
74. 74 Bajou K, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998; 4:923-928.
75. 75 Heymans S, Luttun A, Nuyens D, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure [see Comments]. Nat Med 1999; 5:1135-1142.
76. 76 Moore BB, Keane MP, Addison CL, et al. CXC chemokine modulation of angiogenesis: the importance of balance between angiogenic and angiostatic members of the family. J Invest Med 1998; 46:113-120.
77. 77 Keane MP, Belperio JA, Arenberg DA, et al. IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. J Immunol 1999; 163:5686-5692. This manuscript shows that IP-10 can attenuate fibrosis by the inhibition of angiogenesis.
78. 78 Keane MP, Belperio JA, Arenberg MD, et al. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 1997; 159:1437-1443.